
| Disease Domain | Count |
|---|---|
| Neoplasms | 6 |
| Nervous System Diseases | 3 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
| Recombinant protein | 1 |
| Antibody | 1 |
| Recombinant polypeptide | 1 |
| Fusion protein | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date04 Oct 2025 |
Sponsor / Collaborator |
Start Date15 Aug 2025 |
Sponsor / Collaborator |
Start Date01 Aug 2025 |
Sponsor / Collaborator |



| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Compound 12m(China Medical University) | Neoplasms More | Preclinical |
Compound 12n(China Medical University) | Neoplasms More | Preclinical |
MJ-66 | Glioma More | Preclinical |
SN38-G | Neoplasms More | Preclinical |
CN016 | Chemotherapy-induced damage More | Preclinical |





